News

Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Zacks Investment Research on MSN1h
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...
24/7 Wall St. on MSN2d
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Mounjaro side effects revealed: Decreased appetite, mild nausea and more
Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...
Houston Public Media4d
Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...